Thiabendazole
Mintezol (thiabendazole) is a small molecule pharmaceutical. Thiabendazole was first approved as Mintezol on 1982-01-01. It is used to treat dracunculiasis, helminthiasis, larva migrans, strongyloidiasis, and trichinellosis in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| dracunculiasis | EFO_0007241 | D004320 | B72 |
| helminthiasis | EFO_1001342 | D006373 | B65-B83 |
| larva migrans | EFO_0007391 | D007815 | B76.9 |
| strongyloidiasis | EFO_0007501 | D013322 | B78 |
| trichinellosis | EFO_0007520 | D014235 | B75 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D01: Antifungals for dermatological use
— D01A: Antifungals for topical use
— D01AC: Imidazole and triazole derivatives, topical antifungals
— D01AC06: Tiabendazole
P: Antiparasitic products, insecticides and repellents
— P02: Anthelmintics
— P02C: Antinematodal agents
— P02CA: Benzimidazole derivatives, antinematodal
— P02CA02: Tiabendazole
HCPCS
No data
Clinical
Clinical Trials
4 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fuchs' endothelial dystrophy | D005642 | EFO_0003946 | H18.51 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | THIABENDAZOLE |
| INN | tiabendazole |
| Description | Thiabendazole is a member of the class of benzimidazoles carrying a 1,3-thiazol-4-yl substituent at position 2. A mainly post-harvest fungicide used to control a wide range of diseases including Aspergillus, Botrytis, Cladosporium and Fusarium. It has a role as an antifungal agrochemical and an antinematodal drug. It is a member of benzimidazoles, a member of 1,3-thiazoles and a benzimidazole fungicide. It derives from a hydride of a 1H-benzimidazole. |
| Classification | Small molecule |
| Drug class | antithelmintics (tibendazole type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | c1ccc2[nH]c(-c3cscn3)nc2c1 |
Identifiers
| PDB | — |
| CAS-ID | 148-79-8 |
| RxCUI | 10450 |
| ChEMBL ID | CHEMBL625 |
| ChEBI ID | 45979 |
| PubChem CID | 5430 |
| DrugBank | DB00730 |
| UNII ID | N1Q45E87DT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,965 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
796 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more